|
|
||||||||
J Thorac Cardiovasc Surg 2008;136:424-430
© 2008 The American Association for Thoracic Surgery
Surgery for Acquired Cardiovascular Disease |
a Department of Cardiothoracic Surgery and Division of Interventional Radiology, Stanford University School of Medicine, Stanford, Calif
b Department of Cardiothoracic Surgery, Rennes University School of Medicine, Rennes, France
Received for publication March 19, 2006; revisions received December 31, 2007; accepted for publication January 5, 2008. * Address for reprints: D. Craig Miller, MD, Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University Medical School, 300 Pasteur Drive, Stanford, CA 94305. (Email: dcm{at}stanford.edu).
| Abstract |
|---|
|
|
|---|
Methods: Between November 1996 and June 2004, 16 patients with complicated acute type B aortic dissections (mean age 57 years, range 16–88 years) underwent endovascular stent–grafting within 48 hours of presentation. Complications included contained rupture, hemothorax, refractory chest pain, and severe visceral or lower limb ischemia. Stent–graft types included custom-made first-generation endografts and second-generation commercial stent–grafts (Gore Excluder or TAG; W. L. Gore & Associates, Inc, Flagstaff, Ariz.). Follow-up was 100% complete, averaged 36 ± 36 months, and included postprocedural surveillance computed tomographic scans.
Results: Early mortality was 25% ± 11% (70% confidence limit), with no late deaths. No new neurologic complications occurred. According to the latest scan, 4 patients (25%) had complete thrombosis of the false lumen; the lumen was partially thrombosed in 6 patients (38%). Distal aortic diameter was increased in only 1 patient. Actuarial survival at 1 and 5 years was 73% ± 11%; freedom from treatment failure (including aortic rupture, device fault, reintervention, aortic death, or sudden, unexplained late death) was 67% ± 14% at 5 years.
Conclusion: With follow-up to 9 years, endovascular stent–grafting for patients with complicated acute type B aortic dissection conferred benefit. Consideration of emergency stent–grafting may improve the dismal outlook for these patients; future refinements in stent–graft design and technology and earlier diagnosis and intervention should be associated with improved results.
| Introduction |
|---|
|
|
|---|
Although several reports of patients with aortic dissection treated with stent–grafts have been published, these mixed series frequently commingled type A and type B dissections, acute and chronic dissections, or complicated and uncomplicated cases; further, clinical follow-up has been short, hindering critical assessment of results. We report our midterm stent–graft results in patients with acute type B aortic dissection with life-threatening complications.
| Materials and Methods |
|---|
|
|
|---|
Cases of acute type B aortic dissections were judged to be complicated if one or more of the following four clinical problems were present: (1) ongoing intractable chest pain, despite maximal medical therapy; (2) clinical or radiographic evidence of rupture or impending rupture; (3) symptomatic presentation with an aortic diameter greater than 5 cm or documented rapid aortic enlargement; and (4) symptomatic branch vessel occlusion with distal organ ischemia, as determined by clinical symptoms or laboratory testing.
Patients were excluded if arterial access was inadequate (small [<7 mm] iliac or femoral arteries) or if the PIT was located within 1 cm from the left common carotid artery origin. Patients with Marfan syndrome or other connective tissue disorders were excluded (contraindication to stent–grafting in our institutional review board protocols), but a 16-year-old patient with type IV (vascular type) Ehlers–Danlos syndrome who was initially seen with aortic rupture and paraplegia was treated on a compassionate use basis. Three patients were first seen with a propagating (>20 cm) genuine aortic dissection caused by traumatic aortic disruption at the level of the ligamentum, but patients with isolated traumatic tears and localized traumatic pseudoaneurysms were excluded. Spontaneous dissection was the etiology in the remaining 12 cases.
Preprocedural Imaging
All patients underwent thin-slice CTA with 3-dimensional reconstructions to determine the exact location of the PIT, the distance from the PIT to the left subclavian and carotid arteries, the lengths and diameters of the diseased aortic segments, the morphologic characteristics of the proximal and distal landing zones, the diameters of the true and false lumens, and the mechanism of end-organ malperfusion. The stent–graft was oversized by 10% to 15% relative to the proximal true lumen to make it just slightly larger than the distal aortic arch diameter. When possible, the stent–graft was deployed at least 20 to 40 mm beyond the PIT to ensure adequate wall contact and a tight circumferential seal.
Stent–graft Devices
First-generation stent–grafts were custom fabricated from modified Gianturco Z stents (Cook Medical Inc, Bloomington, Ind) that were wired together and then covered with a woven polyester graft (Boston Scientific Corporation, Natick, Mass). A 20F to 24F pusher-rod sheath delivery system (Cook) was used for deployment of the first-generation devices in the initial 8 patients. Second-generation, commercially manufactured Gore Excluder or TAG stent–grafts became available later and were used in the remaining 8 patients. These devices consist of a self-expanding nitinol exoskeleton lined with expanded polytetrafluoroethylene graft material, require the introducer sheath be inserted only as far as the abdominal aorta, are advanced over a coaxial wire, and are rapidly deployed by a drawstring mechanism that releases a constraining shroud.
Details of stent–graft deployment techniques have been described previously.1,6
With the patient under general anesthesia in an operating room-equipped catheterization laboratory with a Siemens 2300 Imaging System (Siemens Medical Systems, Inc, Ultrasound Group, Issaquah, Wash), transesophageal echocardiography, angiography, and occasionally intravascular ultrasonography were used to define the aortic true and false lumens. After arterial access was gained through either the femoral or iliac artery, a hydrophilic guide wire was advanced into the aortic arch and exchanged for a stiff wire; the delivery system dilator–sheath was then advanced into the aortic true lumen, and the stent–graft was advanced to the target to cover the PIT completely. After optimal positioning of the device, the stent–graft was deployed. Ballooning of the stent–graft was performed only if a large type IA proximal endoleak was documented, and only at the proximal landing zone. When needed, a second stent–graft was placed. Angiography confirmed the absence of endoleaks and determined the perfusion status of previously ischemic arterial beds.
Follow-up and Definitions
Before discharge, at 3, 6, and 12 months, and then annually thereafter, we attempted to obtain follow-up CTA scans for all patients. Aortic diameter was assessed just below the distal end of the stent–graft. Clinical status was ascertained by contacting the patients or their primary physicians. Causes of death were determined by reviewing death certificates and, when available, autopsy reports. Technical success was defined as exclusion of the false lumen with reperfusion of previously ischemic, mesenteric, renal, or lower extremity arterial beds. Treatment failure was defined as a composite end point including perioperative death, primary or secondary endoleaks, late device failure, the necessity for reintervention, late aortic-related death, and all sudden, unexplained late deaths, as previously advocated by our group. Continuous variables are expressed as mean ± SD and median values; important rates and fractions are expressed with 70% confidence limits. The Kaplan–Meier method generated actuarial survival estimates, which are reported SE, which approximates the 70% confidence limits. All statistical analyses were performed with SPSS software (SPSS, Inc, Chicago, Ill).
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
It is difficult to know with certainty the results of endovascular stent–graft repair in patients with complicated acute type B aortic dissections for a host of reasons. Most reports contain both complicated and uncomplicated cases, as well as mixed cases of acute and chronic dissections. Furthermore, most physicians in Europe and South America consider stent–grafting too risky until at least 2 weeks have passed since presentation; such patients with subacute dissections constitute a naturally selected subset. To define complicated acute type B dissection,6,24,25
we considered the threat of continued aortic expansion or rupture and the extent and severity of distal end-organ ischemia. Indicators of high risk included ongoing chest or abdominal pain despite optimal medical therapy, rapid dilation of the aortic false lumen, increasing pleural effusion accompanied by pain, radiographic signs of rupture or impending rupture, evolution of clinical symptoms, and laboratory markers associated with gut ischemia accompanied by signs of compromised visceral perfusion on CTA scan. It is generally accepted that these criteria define a high-risk subgroup of acute type B aortic dissection that requires emergency treatment. Risk of rupture is usually obvious from progressive radiologic signs, clinical instability, and inability to control the pain. Intestinal ischemia, however, may progress more insidiously, with results of abdominal examination potentially remaining unremarkable until visceral infarction has become established. At this stage, gut salvage may not be possible, even after successful abdominal aortic reperfusion. Despite early stent–graft deployment, restoration of adequate branch artery true-lumen perfusion with bare stents, and prompt surgical bowel resection when necessary, death was not preventable in cases of irreversible infarction of two or more vascular beds. At an earlier stage, when reperfusion can still salvage important end organs, patients with malperfusion and evolving visceral ischemia could be identified. A third scenario exists where there is severe malperfusion, usually involving the kidneys, without clinical symptoms. Loss of adequate perfusion to one kidney, despite satisfactory urine output from the contralateral functioning kidney, can eventually result in loss of a functioning kidney.17
In general, three treatment strategies are available. Direct open surgical aortic graft replacement through a left thoracotomy can redirect blood flow into the true lumen and remove the aortic segment with the most trauma. This, however, has historically been associated with high operative risk,13
is invasive, and requires cardiopulmonary bypass and profound hypothermia for an open proximal anastomosis in the arch.10,11
Further, immediate adequacy of distal reperfusion is not easily assessable,18
which may necessitate additional downstream catheter interventional treatment. Endovascular stent–graft repair similarly redirects blood flow into the true lumen, and immediate assessment of the adequacy of distal perfusion is obtained with aortography. Nonreperfused organs cut off by static branch obstruction can then be quickly reperfused with catheter-based dissection flap fenestration or branch true-lumen stenting.6,24
Finally, balloon fenestration of the dissection flap and stenting from the aortic true or false lumen into the true lumen of the ischemic branch vessel is a third alternative, one that was used by our group before the availability of thoracic aortic stent–grafts. All these techniques may be effective in the short term, and each is associated with different degrees of invasiveness, effectiveness, and attendant morbidity. Open surgical aortic repair remains the treatment of choice for patients with major arch involvement, those in whom the PIT is too proximal to allow stent–grafting, and those with Marfan syndrome or other connective tissue disorders.
Limitations of thoracic aortic stent–grafting clearly exist. Multiple reentry fenestrations are usually present in the distal descending thoracic and abdominal aorta, allowing continued perfusion of the false lumen. Although flow through these communications may prevent complete thrombosis of the aortic false lumen, these fenestrations are usually smaller than the PIT and neither cause aortic true-lumen obstruction nor lead to acute rupture of the false lumen. Follow-up studies from Mei University in Japan have shown that late serious aortic complications occur after stent–grafting for aortic dissection, for example, delayed intimal tears caused by the stent–graft or migration of the stent–graft away from the aortic wall along the lesser curve of the distal arch.25,26
Careful, continuous follow-up is essential indefinitely to ensure stability of the stent–graft, persistent patency of important aortic tributaries, and the aortic true- and false-lumen dimensions. The 25% incidence of complete false-lumen thrombosis observed in our experience was higher than that reported after surgical repair of patients with acute type A dissections, but a comparison of the likelihood of false-lumen thrombosis or enlargement is handicapped by the small sample size in this report. Again, our therapeutic goal for patients with acute type B dissections is not so much to eliminate all blood flow in the false lumen as to reperfuse the lower body quickly and prevent thoracic aortic rupture. A persistent proximal type I endoleak, which does not necessarily preclude early success because reperfusion of severely ischemic abdominal end organs is one of the key therapeutic goals, may result in late failure from progressive false-lumen expansion. Type II endoleaks, which may be confused with natural flap reentry fenestrations, however, do not connote failure and usually can be followed up observationally unless they result in progressive false-lumen aneurysmal dilation. In this experience, aortic diameter in the absence of an endoleak remained stable at midterm follow-up in most cases. Additional follow-up of a larger number of patients, however, is clearly mandatory to elucidate the long-term results of stent–grafting in patients with complicated acute type B dissections.
Although stent–graft repair is an attractive alternative because it is less invasive, angiography requires the use of iodinated contrast, which can exacerbate preexisting ischemic renal injury. Technologic limitations also exist. Half of the deaths in this series were due to aortic rupture and represent treatment failure. The acutely dissected aorta and flap are exceptionally fragile and thin, calling for special, disease-specific endograft designs that currently are lacking. The ideal stent–graft for acute dissection should be able to be fixed securely in the distal arch without hooks, must be soft and flexible to allow maneuvering within the arch without creation of a retrograde type A dissection, and must conform readily to the sharp curvature of the distal arch to avoid proximal endoleaks. The ideal stent–graft for acute dissections should also have sufficient radial strength to expand the true lumen, thus promoting false-lumen thrombosis without further intimal flap injury. Advances in stent–graft technology and newer disease-specific stent–grafts should translate into better results in the future. Finally, avoiding coverage of the distal half of the descending thoracic aorta is important in minimizing the likelihood of paraplegia.
In summary, emergency endovascular thoracic aortic stent–graft repair for patients with complicated acute type B dissections saves lives and is effective to 5 years. Promising observations in this report with extended follow-up include the absence of late deaths and the reasonable stability of the stent–graft. Stent–grafting rapidly reverses life-threatening malperfusion in cases of true-lumen collapse and probably minimizes the risk of rupture as well. Because of the high-risk nature of this patient population, it is unrealistic to expect that the mortality risk will approach zero; if the life-threatening consequences of acute distal malperfusion can be reversed early enough and the patient stabilized, more patients will survive the early high risk phase. Then the patient can be followed up clinically and the dissected aorta monitored carefully with serial scans. If false-lumen enlargement occurs, delayed open surgical repair can be performed in elective circumstances with a reasonably low risk. Finally, the long-term (5–10 years) effectiveness and durability of thoracic stent–grafting for acute type B aortic dissection will remain unknown until the results of larger studies with long-term follow-up are available.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
O. Jazaeri, R. Gupta, P. J. Rochon, and T. B. Reece Endovascular Approaches and Perioperative Considerations in Acute Aortic Dissection Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2011; 15(4): 141 - 162. [Abstract] [PDF] |
||||
![]() |
S. Trimarchi, F. H. W. Jonker, S. Hutchison, E. M. Isselbacher, L. A. Pape, H. J. Patel, J. B. Froehlich, B. E. Muhs, V. Rampoldi, V. Grassi, et al. Descending aortic diameter of 5.5 cm or greater is not an accurate predictor of acute type B aortic dissection J. Thorac. Cardiovasc. Surg., September 1, 2011; 142(3): e101 - e107. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Jing-dong, H. Jun-feng, Z. Ke-qiang, H. Wen-zhao, Y. Ming-feng, F. Wei-guo, and W. Yu-qi Emergency endovascular repair of complicated Stanford type B aortic dissections within 24 hours of symptom onset in 30 cases J. Thorac. Cardiovasc. Surg., April 1, 2011; 141(4): 926 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Naughton, M. Garcia-Toca, J. S. Matsumura, H. E. Rodriguez, M. D. Morasch, S. A. Resnick, and M. K. Eskandari Complicated Acute Type B Thoracic Aortic Dissections: Endovascular Treatment For Visceral Malperfusion And Pseudoaneurysms Vascular and Endovascular Surgery, April 1, 2011; 45(3): 219 - 226. [Abstract] [PDF] |
||||
![]() |
M. L. Field, M. Kuduvalli, and A. Oo Multidisciplinary team-led management of acute Type B aortic dissection in the United Kingdom? J R Soc Med, February 1, 2011; 104(2): 53 - 58. [Full Text] [PDF] |
||||
![]() |
S. Trimarchi, K. A. Eagle, C. A. Nienaber, R. E. Pyeritz, F. H. W. Jonker, T. Suzuki, P. T. O'Gara, S. J. Hutchinson, V. Rampoldi, V. Grassi, et al. Importance of Refractory Pain and Hypertension in Acute Type B Aortic Dissection: Insights From the International Registry of Acute Aortic Dissection (IRAD) Circulation, September 28, 2010; 122(13): 1283 - 1289. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ueda, D. Fleischmann, M. D. Dake, G. D. Rubin, and D. Y. Sze Incomplete Endograft Apposition to the Aortic Arch: Bird-Beak Configuration Increases Risk of Endoleak Formation after Thoracic Endovascular Aortic Repair Radiology, May 1, 2010; 255(2): 645 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Y. Sze, M. A.A.J. van den Bosch, M. D. Dake, D. C. Miller, L. V. Hofmann, R. Varghese, S. C. Malaisrie, P. J.A. van der Starre, J. Rosenberg, and R. S. Mitchell Factors Portending Endoleak Formation After Thoracic Aortic Stent-Graft Repair of Complicated Aortic Dissection Circ Cardiovasc Interv, April 1, 2009; 2(2): 105 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Miyamoto Invited Commentary Ann. Thorac. Surg., January 1, 2009; 87(1): 108 - 108. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |